While interest in using fibrates as PPARα agonist for NAFLD and NASH has dwindled, there is much enthusiasm in selective PPAR alpha modulator (SPPARMα) such as pemafibrate to enhance clinical efficacy and minimize side effects. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.